Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to SARS-CoV-2 Vaccines in MS Patients on Ofatumumab
NCT04869358Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started May 2021; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04869358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869358.